Treatment of pulmonary embolism: The use of low-molecularweight heparin in the inpatient and outpatient settings

Russell D. Hull

doi:10.1160/TH07-08-0500

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 99(03): 502-510
DOI: 10.1160/TH07-08-0500

Review Article

Schattauer GmbH

Treatment of pulmonary embolism: The use of low-molecularweight heparin in the inpatient and outpatient settings

Russell D. Hull

Abstract

Summary

Pulmonary embolism (PE) remains a major clinical problem associated with considerable mortality and morbidity. In patients with PE, appropriate anticoagulant therapy has been shown to significantly reduce both recurrence and mortality. Low-molecular- weight heparin (LMWH) is at least as effective as unfractionated heparin (UFH) in the treatment of PE,with a similar risk of bleeding. Furthermore, LMWH offers more predictable pharmacokinetics and anticoagulant effects. As a result, current guidelines from both the American College of Chest Physicians and the joint American College of Physicians/American Academy of Family Physicians recommend the use of LMWH over UFH (in patients with submassive PE). Outpatient treatment with LMWH has been shown to be feasible in many patients,and offers the potential for cost-savings and improvements in healthrelated quality of life. Further data are needed to support an evidence- based recommendation for the use of LMWH in the outpatient treatment of PE.

Keywords

Anticoagulants - low-molecular-weight heparin - pulmonary embolism - thromboembolism

Full Text

References

References
1 Heit JA, Cohen AT, Anderson Jr FA. et al. on the behalf of the VTE Impact Assessment Group Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the U.S. ASH Annual Meeting Abstracts. Blood 2005; 106 Abstract 910.
2 White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (Suppl. 23) 1I I4-I8.
3 White RH, Zhou H, Murin S. et al. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 2005; 93: 298-305.
4 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registery (ICOPER). Lancet 1999; 353: 1386-1389.
5 Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?. J R Soc Med 1989; 82: 203-205.
6 Geerts WH, Pineo GF, Heit JA. et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 338S-400S.
7 Büller HR, Agnelli G, Hull RD. et al. Antithrombotic therapy for venous thromboembolic disease: theSeventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 401S-428S.
8 Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; 1: 1309-1312.
9 Quinlan DJ, McQuillan A, Eikelboom JW. Lowmolecular- weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: A meta-analysis of randomized, controlled trials. Ann Intern Med 2004; 140: 175-183.
10 Hirsh J, Raschke R. Heparin and low-molecularweight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 188S-203S.
11 Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 311S-337S.
12 Levine M, Gent M, Hirsh J. et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-681.
13 Koopman MMW, Prandoni P, Piovella F. et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334: 682-687.
14 Hull RD, Raskob GE, Pineo GF. et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximalvein thrombosis. N Engl J Med 1992; 326: 975-982.
15 Prandoni P, Lensing AW, Büller HR. et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deepvein thrombosis. Lancet 1992; 339: 441-445.
16 Levine M, Gent M, Hirsh J. et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-681.
17 Koopman MM, Prandoni P, Piovella F. et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334: 682-687.
18 The COLUMBUS Investigators. Low-molecularweight heparin in the treatment of patients with pulmonary embolism venous thromboembolism. The COLUMBUS Investigators. N Engl J Med 1997; 337: 657-662.
19 Merli G, Spiro TE, Olsson C-G. et al Enoxaparin Clinical Trial Group. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001; 134: 191-202.
20 Kearon C, Ginsberg JS, Julian JA. et al Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixeddose weight-adjusted unfractionated heparin and lowmolecular- weight heparin for acute treatment of venous thromboembolism. J Am Med Assoc 2006; 296: 935-942.
21 Prandoni P, Carnovali M, Marchiori A. The Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 2004; 164: 1077-1083.
22 Mismetti P, Quenet S, Levine M. et al. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. Chest 2005; 128: 2203-2210.
23 Dager WE, King JH, Branch JM. et al. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis. Ann Pharmacother 2005; 39: 1182-1187.
24 Théry C, Simonneau G, Meyer G. et al. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation 1992; 85: 1380-1389.
25 Meyer G, Brenot F, Pacouret G. et al. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. Thromb Haemost 1995; 74: 1432-1435.
26 Findik S, Erkan ML, Selcuk MB. et al. Low-molecular- weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration 2002; 69: 440-444.
27 Lim AYH, Parr DG, Stableforth DE. et al. Early discharge and home supervision of patients with pulmonary embolism treated with low-molecular weight heparin. Eur J Intern Med 2003; 14: 89-93.
28 Olsson CG, Bitzen U, Olsson B. et al. Outpatient tinzaparin therapy in pulmonary embolism quantified with ventilation/perfusion scintigraphy. Med Sci Monit 2006; 12: PI9-13.
29 Simonneau G, Sors H, Charbonnier B. et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l’Embolie Polmonaire. N Engl J Med 1997; 337: 663-669.
30 Hull RD, Raskob GE, Brant RF. et al. Low-molecular- weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 2000; 160: 229-236.
31 Kovacs MJ, Anderson D, Morrow B. et al. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost 2000; 83: 209-211.
32 Wells PS, Anderson DR, Rodger MA. et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005; 165: 733-738.
33 Wells PS, Kovacs MJ, Bormanis J. et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular- weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998; 158: 1809-1812.
34 Gould MK, Dembitzer AD, Doyle RL. et al. Lowmolecular- weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-809.
35 Dolovich LR, Ginsberg JS, Douketis JD. et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160: 181-188.
36 Geerts WH, Pineo GF, Heit JA. et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 338S-400S.
37 Guyatt G, Schünemann HJ, Cook D. et al. Applying the grades of recommendations for antithrombotic and thrombolytic therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 179S-187S.
38 Snow V, Qaseem A, Barry P. et al American College of Physicians; American Academy of Family Physicians Panel on Deep Venous Thrombosis/Pulmonary Embolism. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2007; 146: 204-210.
39 British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 2003; 58: 470-483.
40 GlaxoSmithKline, October 2005. Arixtra® (fondaparinux sodium) injection prescribing information. Available at: http://us.gsk.com/products/assets/ us_arixtra.pdf. Accessed May 22, 2007.
41 Segal JB, Streiff MB, Hofmann LV. et al. Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med 2007; 146: 211-222.
42 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registery (ICOPER). Lancet 1999; 353: 1386-1389.
43 Becattini C, Agnelli G. Risk factors for adverse short-term outcome in patients with pulmonary embolism. Thrombosis Res 2001; 103: V239-244.
44 Heit JA, Silverstein MD, Mohr DN. et al. Predictors of survival after deep vein thrombosis and pulmonary embolism. A population-based, cohort study. Arch Intern Med 1999; 159: 445-453.
45 Aujesky D, Roy PM, Guy M, Cornuz J. et al. Prognostic value of D-dimer in patients with pulmonary embolism. Thromb Haemost 2006; 96: 478-482.
46 Merli GJ. Pulmonary embolism in medical patients: improved diagnosis and the role of low-molecular- weight heparin in prevention and treatment. J Thromb Thrombolysis 2004; 18: 117-125.
47 Al Mahameed A, Carman TL. Outpatient management of stable acute PE: proposed accelerated pathway for risk stratification. Am J Med 2007; 120: S18-25.
48 Wicki J, Perrier A, Perneger TV. et al. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 2000; 84: 548-552.
49 Nendaz MR, Bandelier P, Aujesky D. et al. Validation of a risk score identifying patients with acute pulmonary embolism, who are at low risk of clinical adverse outcome. Thromb Haemost 2004; 91: 1232-1236.
50 Aujesky D, Obrosky DS, Stone RA. et al. A prediction rule to identify low-risk patients with pulmonary embolism. Arch Intern Med 2006; 166: 169-175.
51 Aujesky D, Perrier A, Roy PM. et al. Validation of a clinical prognostic model to identify low-risk patients with pulmonary embolism. J Intern Med 2007; 261: 597-604.
52 Jimenez D, Yusen RD, Otero R. et al. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Chest 2007; 132: 24-30.
53 Beer JH, Burger M, Gretener S. et al. Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients [letter]. J Thromb Thrombolysis 2003; 1: 186-187.
54 Tanvetyanon T, Cohn JB. Eligibility for outpatient treatment with low-molecular-weight heparin in venous thromboembolism. Arch Intern Med 2000; 160: 869-870.
55 Jimenez D, Diaz G, Marin E. et al. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymp-tomatic pulmonary embolism. Thromb Haemost 2006; 95: 562-566.
56 Eichinger S, Weltermann A, Minar E, Stain M, Schönauer V, Schneider B, Kyrle PA. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 2004; 164: 92-96.
57 Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 2004; 24: 1311-1316.
58 Ansell J, Hirsh J, Poller L. et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S-233S.
59 Lee AYY, Levine MN, Baker RI. et al Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
60 Castro DJ, Diaz G, Marti D. et al. Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism. Blood Coagul Fibrinolysis 2007; 18: 173-177.
61 Hull RD, Pineo GF, Brant RF. et al LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-1072.
62 Hull RD, Pineo GF, Brant RF. et al LITE Trial Investigators. Self-managed long-term low-molecularweight heparin therapy: the balance of benefits and harms. Am J Med 2007; 120: 72-82.
63 Ferretti G, Bria E, Giannarelli D. et al. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?. Chest 2006; 130: 1808-1816.
64 Arcelus JI, Caprini JA, Monreal M. et al. The management and outcome of acute venous thromboembolism: a prospective registry including 4011 patients. J Vasc Surg 2003; 38: 916-922.
65 Douketis JD, Kearon C, Bates S. et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. J Am Med Assoc 1998; 279: 458-462.
66 Panis LJGG, Kolbach DN, Hamulyák K. et al. Identifying inappropriate hospital stay in patients with venous thromboembolism. Eur J Intern Med 2004; 15: 39-44.
67 Knight KK, Wong J, Hauch O. et al. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients. Value Health 2005; 8: 191-200.
68 Hull RD, Raskob GE, Rosenbloom D. et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med 1997; 157: 289-294.
69 O’Brien B, Levine M, Willan A. et al. Economic evaluation of outpatient treatment with low-molecularweight heparin for proximal vein thrombosis. Arch Intern Med 1999; 159: 2298-2304.
70 Smith BJ, Weekley JS, Pilotto L. et al. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin. Intern Med J 2002; 32: 29-34.
71 Aujesky D, Smith KJ, Cornuz J. et al. Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. Chest 2005; 128: 1601-1610.